John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed refractory (R/R) chronic lymphocytic leukemia (CLL).
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
